Laekna, Inc., a company incorporated in the Cayman Islands, has announced the presentation of clinical and preclinical study results for its drug candidates, LAE02, LAE03, and LAE123, at the 85th scientific sessions of the American Diabetes Association $(ADA.AU)$ held in 2025. The studies focused on the potential use of these drugs for muscle growth and fat reduction. The results included data from the phase I SAD study of LAE102, an ActRIIA-selective antibody, for treating obesity. This study involved both intravenous and subcutaneous cohorts and concluded that LAE102 was well tolerated, with no serious adverse events reported. The presentations took place on June 22, 2025, at the McCormick Place Convention Center in Chicago, Illinois, USA. Shareholders and potential investors are advised to exercise caution, as these drug candidates may not ultimately be successfully developed and commercialized.